Amarin failed to convince a federal appeals court to revive key patents covering its heart drug Vascepa. The decision, announced Thursday, exposes the company’s only drug to generic competition in the U.S.
The ruling comes just one day after oral arguments and affirms an earlier court decision that some patents covering Vascepa were “obvious” and thus unenforceable. The ruling is a victory for Hikma Pharmaceuticals and Dr. Reddy’s Laboratories, two companies planning to sell generic versions of Vascepa.
About the Author Reprints
